This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Enfusion, Inc. (ENFN) Q1 Earnings Meet Estimates
by Zacks Equity Research
Enfusion, Inc. (ENFN) delivered earnings and revenue surprises of 0% and 2.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Enfusion and Granite Construction have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Enfusion and Granite Construction are part of the Zacks Bull and Bear of the Day article.
Bull Of The Day: Enfusion (ENFN)
by Brian Bolan
This stock has some good historical and projected topline growth.
BCE's Q1 Earnings Beat Estimates, Revenues Increase Y/Y
by Zacks Equity Research
BCE's first-quarter performance benefits from solid residential Internet growth and higher Bell CTS sales.
DoorDash (DASH) Reports Q1 Loss, Beats Revenue Estimates
by Zacks Equity Research
DoorDash's (DASH) first-quarter 2023 results reflect higher costs despite a significant rise in total orders.
BILL Holdings (BILL) Q3 Earnings Top Estimates, Revenues Up Y/Y
by Zacks Equity Research
BILL Holdings' (BILL) third-quarter fiscal 2023 results reflect solid growth in its standalone BILL Platform and Divvy spend management solution.
Shopify (SHOP) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Shopify's (SHOP) first-quarter 2023 results benefit from growth in merchant solutions revenues and an expanding merchant base.
Microchip (MCHP) Q4 Earnings Top Estimates, Sales Rise Y/Y
by Zacks Equity Research
Microchip's (MCHP) fourth-quarter fiscal 2023 results reflect continued momentum in the mixed-signal microcontroller business.
Apple (AAPL) Q2 Earnings Beat Estimates, Revenues Decline Y/Y
by Zacks Equity Research
Apple's (AAPL) second-quarter fiscal 2023 results benefit from strong demand for iPhone 14 amid significant forex headwind and challenging macroenvironment conditions.
Enfusion (ENFN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Enfusion's (ENFN) first-quarter 2023 performance is expected to have benefited from healthy demand, new clients and improving margins.
Datadog (DDOG) Q1 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Datadog's (DDOG) first-quarter 2023 top line benefits from customers' attraction toward new innovations.
Dolby's (DLB) Q2 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
Dolby's (DLB) second-quarter fiscal 2023 performance benefits from revenue growth across all business segments and increased adoption of Dolby Atmos and Dolby Vision.
TELUS (TU) Q1 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
TELUS's (TU) first-quarter performance gains from high service revenues in TELUS technology solutions and TELUS International.
Cirrus Logic (CRUS) Q4 Earnings Top Estimates, Down Y/Y
by Zacks Equity Research
Cirrus Logic's (CRUS) fourth-quarter fiscal 2023 performance declines due to lower general market sales and reduced smartphone sales.
ANSYS (ANSS) Q1 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
ANSYS's (ANSS) first-quarter performance benefits from strength in the aerospace and defense, high-tech and automotive sectors
Watts Water (WTS) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Watts Water's (WTS) first-quarter performance improves due to momentum across APMEA and the Americas amid rising inflation.
CDW's Q1 Earnings & Revenues Surpass Estimates, Down Y/Y
by Zacks Equity Research
CDW's first-quarter 2023 performance is affected due to weakness across all business segments and weakening IT spending.
Lumen (LUMN) Q1 Earnings Miss Estimates, Revenues Down Y/Y
by Zacks Equity Research
Lumen's (LUMN) first-quarter 2023 performance is affected by the completion of the sale of its Latin America business and its 20-state ILEC business to Apollo.
Enfusion, Inc. (ENFN) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
In the latest trading session, Enfusion, Inc. (ENFN) closed at $8.56, marking no change from the previous day.
Enfusion, Inc. (ENFN) Q1 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Enfusion, Inc. (ENFN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SNAP's Q1 Earnings Increase Y/Y, Revenues Miss Estimates
by Zacks Equity Research
SNAP's first-quarter 2023 results reflect steady user growth and an increase in Snapchat+ users amid a fall in average revenues per user.
Bears are Losing Control Over Enfusion, Inc. (ENFN), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Enfusion, Inc. (ENFN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Enfusion, Inc. (ENFN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Enfusion, Inc. (ENFN) closed at $8.74, marking a +0.69% move from the previous day.
After Plunging -14.72% in 4 Weeks, Here's Why the Trend Might Reverse for Enfusion, Inc. (ENFN)
by Zacks Equity Research
Enfusion, Inc. (ENFN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Best Momentum Stock to Buy for March 29th
by Zacks Equity Research
NUE, ENFN and TRIN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 29, 2023.